Navigation Links
Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine

Vaxfectin(TM) may have potential applications as an adjuvant for other protein-based vaccines as well. The company holds patents in the United States covering Vaxfectin(TM) and its use with conventional vaccines against infectious diseases and cancer, and in both the United States and Europe covering the use of Vaxfectin(TM) with DNA vaccines.

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether Vical or others will continue evaluation of Vaxfectin(TM) as an adjuvant for conventional vaccines against seasonal or pandemic influenza; whether Vaxfectin(TM) will be used as a dose-sparing agent with conventional influenza vaccines against seasonal or pandemic influenza strains; whether Vical or others will continue development of the pandemic influenza DNA vaccine cand
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
2. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
3. New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
4. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
5. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
6. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
7. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
8. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
9. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
10. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
11. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:7/6/2015)... -- Cardinal Health today announced the completion of the ... generic pharmaceuticals, over-the-counter medications and related products to retail, ... Court Square Capital Partners. The $1.115 billion acquisition was ... Headquartered in Livonia, Mich. ... approximately $450 million in 2014. There are 450 employees ...
(Date:7/6/2015)... N.J. and FARMINGTON, Conn. ... Inc. (NYSE MKT: PTN), a biopharmaceutical company developing ... diseases with significant unmet medical need and commercial ... a private placement of Series E warrants to ... Series F warrants to purchase 2,191,781 shares of ...
(Date:7/6/2015)... 2015   Cepheid (Nasdaq: CPHD ) today ... 2015 second quarter ended June 30, 2015 on Thursday, ... The Company will host a management presentation ... 2015, to discuss the results.  To access the live ... at least 15 minutes before the scheduled start time ...
Breaking Medicine Technology:Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 2Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 3Palatin Technologies Completes $30 Million Financing 2Palatin Technologies Completes $30 Million Financing 3Palatin Technologies Completes $30 Million Financing 4Palatin Technologies Completes $30 Million Financing 5
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), ... human disease, announced today that results from the Phase ... with non-constipating irritable bowel syndrome (IBS) were published earlier ... journal Gastroenterology .  The issue also included an ...
... National Minority Quality Forum Issue Brief (Specialty Tiering: ... Puckrein and Gretchen Wartman examine specialty tiering, ... as a benefit-management tool to limit their financial exposure ... prescription drugs. The authors remind us that, the Institute ...
Cached Medicine Technology:Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology 2Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology 3Prescription-Drug Plans' Use of Specialty Tiers Promotes Inequalities 2
(Date:7/6/2015)... ... ... Shortly after opening her second practice in Signal Hill, Dr. Sue Lim ... lien basis. Dr. Lim had previously worked with Dr. Kevin Kelly, DC a ... Lim suffered with back pain herself throughout high school. Unaware of the benefits ...
(Date:7/6/2015)... ... July 06, 2015 , ... Invitation to ... yet there is a large gap between the unmet health priorities in the ... health outcomes and reduce unnecessary or ineffective treatments or procedures. , This milestone ...
(Date:7/6/2015)... , ... July 06, 2015 , ... The Asian-Pacific market ... 2014. It is expected to grow at a CAGR of over 3.2 percent in ... The growth is likely to be mainly spurred by an anticipated launch of a ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... radiology services and ADVOCATE is leading the transition. ADVOCATE, the only 100% radiology, ... their Top 10 Tips for ICD-10. The ten tips are timely and relevant ...
(Date:7/6/2015)... ... 06, 2015 , ... Longevity, the highest regarded provider of ... Urgent Care to offer on-site health screenings. These ultrasound screenings detect early signs ... and accurate and run about an hour long with same day results. , ...
Breaking Medicine News(10 mins):Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2Health News:ADVOCATE Takes the Lead to Ensure ICD-10 Success: “Top 10 Tips for ICD-10” 2Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2
... do not fare as well as men when it comes ... Germany now confirm what has long been suspected - kidneys, ... be rejected// by the recipients than those from males. Female ... ,The study covered more than 114,000 kidney transplants, ...
... Contractures are very common in patients who undergo lower ... is important to prevent such complications. That patient ... bent position, which is incorrect.// The correct position is ... are taught to the patient for all the limbs ...
... West Indian Cherry or Acerola fruit (Malpighia Punicifolia L) ... man. Hundred grams of edible portion yields 1000 to ... tree grows well in the tropical parts in India. ... rich in Vitamin A, potassium, calcium, phosphorus and carbohydrates. ...
... that they have found a innovative way to fight deadly ... recognize and fight the patient's own tumor, then inject the ... work.// ,Known as adoptive transfer, the experimental technique involves ... attacking foreign cells that have entered the body. In the ...
... is observed that a surgically implanted shunt could help slow ... cerebrospinal fluid. This type of shunting was first used in ... when there seemed to be a high incidence of side ... of shunting on patients with abnormal amounts of spinal fluid ...
... in UK inserting a coil into a weakened blood vessel ... death rate from subarachnoid haemorrhage// - caused by a bursting ... up to 40 per cent in the first 24 hours ... insert a clip to prevent further rupture of the blood ...
Cached Medicine News:
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: